Charles Schwab Investment Management Inc. Sells 48,005 Shares of OraSure Technologies, Inc. (NASDAQ:OSUR)

Charles Schwab Investment Management Inc. trimmed its position in shares of OraSure Technologies, Inc. (NASDAQ:OSUR) by 6.5% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 694,634 shares of the medical instruments supplier’s stock after selling 48,005 shares during the period. Charles Schwab Investment Management Inc. owned about 0.93% of OraSure Technologies worth $2,966,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in OSUR. Intech Investment Management LLC bought a new position in shares of OraSure Technologies during the third quarter valued at approximately $84,000. Connor Clark & Lunn Investment Management Ltd. boosted its holdings in OraSure Technologies by 78.2% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 28,731 shares of the medical instruments supplier’s stock valued at $123,000 after acquiring an additional 12,604 shares during the period. Factorial Partners LLC grew its position in OraSure Technologies by 12.0% in the 3rd quarter. Factorial Partners LLC now owns 339,953 shares of the medical instruments supplier’s stock valued at $1,452,000 after acquiring an additional 36,326 shares during the last quarter. Empowered Funds LLC increased its stake in OraSure Technologies by 22.6% in the third quarter. Empowered Funds LLC now owns 359,419 shares of the medical instruments supplier’s stock worth $1,535,000 after purchasing an additional 66,210 shares during the period. Finally, Principal Financial Group Inc. lifted its position in shares of OraSure Technologies by 28.1% during the third quarter. Principal Financial Group Inc. now owns 66,060 shares of the medical instruments supplier’s stock worth $282,000 after purchasing an additional 14,480 shares during the last quarter. 93.50% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, StockNews.com cut shares of OraSure Technologies from a “buy” rating to a “hold” rating in a report on Monday, December 9th.

OraSure Technologies Stock Performance

OraSure Technologies stock opened at $3.91 on Friday. OraSure Technologies, Inc. has a fifty-two week low of $3.72 and a fifty-two week high of $8.45. The company has a market capitalization of $291.66 million, a PE ratio of 26.07 and a beta of 0.03. The company has a 50 day moving average price of $4.03 and a 200-day moving average price of $4.23.

OraSure Technologies (NASDAQ:OSUR) last issued its earnings results on Wednesday, November 6th. The medical instruments supplier reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.02. The business had revenue of $39.92 million during the quarter, compared to analysts’ expectations of $38.97 million. OraSure Technologies had a return on equity of 3.55% and a net margin of 5.07%. The business’s revenue for the quarter was down 55.2% compared to the same quarter last year. During the same period in the prior year, the business earned $0.27 EPS. On average, analysts forecast that OraSure Technologies, Inc. will post -0.08 earnings per share for the current year.

OraSure Technologies Profile

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.